Ahmet AYKAS
(Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Genel Cerrahi ve Transplantasyon Bölümü, İzmir, Türkiye)
Erhan TATAR
(Sağlık Bilimleri Üniversitesi, İzmir Bozyaka Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İzmir, Türkiye)
Yıl: 2019Cilt: 28Sayı: 2ISSN: 1300-7718 / 2667-4440Sayfa Aralığı: 98 - 102İngilizce

18 0
Long-Term Follow-up Results of Living Kidney Donors: 20 Years of Experience
Objective: We aimed to retrospectively evaluate the follow-up results of living kidney donors (LKD) at our center since 1997. Materials and Methods: LKD instances between 1997 and 2016 were evaluated. Followed-up by at least one year post-donation were included. The criterion for progression in renal failure (RF) was more than 25% reduction in the glomerular filtration rate (GFR). The cases were divided into two groups: Group 1 (GFR<60 mL/min/1.73 m²) and Group 2 (GFR≥60 mL/ min/1.73 m²) according to the GFR values obtained at the last follow-up. Results: In this study, 205 cases were included. The mean follow-up period was 57±46 (12–215) months. The prevalence of hypertension (all of them were stage 1) and diabetes (83.3% of them were new diagnosis with no end-organ damage) before and after donation was 3.1 and 2.9% vs. 13.3 and 17.5%, respectively (p<0.05). Progressive decline in RF was observed in 29 cases (14%). None of the donors progressed to end-stage renal disease (ESRD). When compared with Group 2, Group 1 patients were older, more frequently hypertensive, and had lower GFR and higher serum uric acid levels. Conclusion: Despite the loss of GFR due to nephrectomy, the progression to RF is rare in LKD. Baseline GFR, uric acid, and age are associated with RF progression. There is a need for a “national donor follow-up program” in Turkey.
DergiAraştırma MakalesiErişime Açık
  • 1. https://organkds.saglik.gov.tr/KamuyaAcikRapor.aspx?q=ORGANNAKLI
  • 2. Lentine KL, Patel A. Risks and outcomes of living donation. Adv Chronic Kidney Dis 2012; 19: 220-8. [CrossRef]
  • 3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
  • 4. Wainright JL, Robinson AM, Wilk AR, Klassen DK, Cherikh WS, Stewart DE. Risk of ESRD in prior living kidney donors. Am J Transplant 2018; 18: 1129-39. [CrossRef]
  • 5. Ibrahim HN, Foley RN, Reule SA, Spong R, Kukla A, Issa N, Berglund DM, Sieger GK, Matas AJ. Renal function profile in white kidney donors: The first 4 decades. J Am Soc Nephrol 2016; 27: 2885-93. [CrossRef]
  • 6. Li SS, Huang YM, Wang M, Shen J, Lin BJ, Sui Y, et al. A meta-analysis of renal outcomes in living kidney donors. Medicine (Baltimore) 2016; 95: e3847. [CrossRef]
  • 7. O’Keeffe LM, Ramond A, Oliver-Williams C, Willeit P, Paige E, Trotter P, et al. Mid- and Long-Term Health Risks in Living Kidney Donors: A Systematic Review and Meta-analysis. Ann Intern Med 2018; 168: 276-84. [CrossRef]
  • 8. Tatar E, Uslu A, Tasli F, Karatas M. Relationship between diurnal blood pressure and renal histopathological changes in white coat hypertension. J Nephrol 2017; 30: 551-6. [CrossRef]
  • 9. Cicero AF, Rosticci M, Bove M, Fogacci F, Giovannini M, Urso R, et al. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study. Ann Med 2017; 49: 275-82. [CrossRef]
  • 10. Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G, et al. Uric acid and new onset left ventricular hypertrophy: Findings from the PAMELA population. Am J Hypertens 2017; 30: 279-85. [CrossRef]
  • 11. Lambert EA, Hachem M, Hemmes R, Straznicky NE, Eikelis N, Sari CI, et al. Serum uric acid and the relationship with subclinical organ damage in adults. J Hypertens 2017; 35: 745-52. [CrossRef]
  • 12. Yadav D, Lee ES, Kim HM, Choi E, Lee EY, Lim JS, et al. Prospective study of serum uric acid levels and incident metabolic syndrome in a Korean rural cohort. Atherosclerosis 2015; 241: 271-7. [CrossRef]
  • 13. Chou YC, Kuan JC, Yang T, Chou WY, Hsieh PC, Bai CH, et al. Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements. J Nephrol 2015; 28: 457-62. [CrossRef]
  • 14. Garg AX, Prasad GV, Thiessen-Philbrook HR, Ping L, Melo M, Gibney EM, et al. Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation 2008; 86: 399-406. [CrossRef]
  • 15. Boudville N, Prasad GV, Knoll G, Muirhead N, Thiessen-Philbrook H, Yang RC, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med 2006; 145: 185-96. [CrossRef]
  • 16. Locke JE, Reed RD, Massie A, MacLennan PA, Sawinski D, Kumar V, et al. Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney Int 2017; 91: 699-703. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.